Different Dosing Regimens of STOP-AST

Sponsor
Eye & ENT Hospital of Fudan University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06124703
Collaborator
(none)
162
2
12.7

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to learn about the different dose regimens of the efficacy of oral steroids in the acute tinnitus population. Participants will receive different appropriate dosages of prednisone tablets and oral Ginkgo Biloba tablets.

Condition or Disease Intervention/Treatment Phase
  • Drug: Prednisone tablet
  • Drug: Ginkgo Biloba Extract
N/A

Detailed Description

The purpose of this clinical study was to investigate the efficacy and to compare two different oral doses of short-term systemic steroid therapy for acute tinnitus.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
162 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparing Two Dosing Regimens of the Efficacy of Short-term Oral Prednisone Therapy on Acute Subjective Tinnitus
Anticipated Study Start Date :
Nov 10, 2023
Anticipated Primary Completion Date :
Feb 10, 2024
Anticipated Study Completion Date :
Nov 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: dose-tapering regimen

The dose selection of oral prednisone is the maximum daily dose for 4 days, followed by a taper every 2 days

Drug: Prednisone tablet
Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
Other Names:
  • Prednisone
  • Drug: Ginkgo Biloba Extract
    Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
    Other Names:
  • EGb
  • Experimental: no taper regimen

    The dose selection of oral prednisone is the maximum daily dose, applied for 5 consecutive days

    Drug: Prednisone tablet
    Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
    Other Names:
  • Prednisone
  • Drug: Ginkgo Biloba Extract
    Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
    Other Names:
  • EGb
  • Outcome Measures

    Primary Outcome Measures

    1. tinnitus handicap inventory (THI) [one week from baseline]

      The THI is a self-administered test, including 25 questions with grades four categories of tinnitus severity: slight corresponding to a score of 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus

    2. tinnitus handicap inventory (THI) [two weeks from baseline]

      The THI is a self-administered test, including 25 questions with grades four categories of tinnitus severity: slight corresponding to a score of 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus

    3. tinnitus handicap inventory (THI) [one month from baseline]

      The THI is a self-administered test, including 25 questions with grades four categories of tinnitus severity: slight corresponding to a score of 0-16, mild (18-36), moderate (38-56), severe (58-100). The higher the score the more severe the tinnitus

    Secondary Outcome Measures

    1. visual analog scale (VAS) [one week from baseline]

      mark the severity of tinnitus on a horizontal scale from 0 to 10. The higher the score, the more severe the symptoms.

    2. visual analog scale (VAS) [two weeks from baseline]

      mark the severity of tinnitus on a horizontal scale from 0 to 10. The higher the score, the more severe the symptoms.

    3. visual analog scale (VAS) [one month from baseline]

      mark the severity of tinnitus on a horizontal scale from 0 to 10. The higher the score, the more severe the symptoms.

    4. the Athens Insomnia Scale-8 (AIS-8) [one week from baseline]

      The AIS comprises eight items that commonly measure difficulties in falling asleep or maintaining sleep to quantify the presence of insomnia. The higher the AIS score, the lower the sleep quality and mental status. The AIS identifies three types of sleep disorders: no insomnia (score below 4), suspicious (4-6), and insomnia (score between 7-24).

    5. the Athens Insomnia Scale-8 (AIS-8) [two weeks from baseline]

      The AIS comprises eight items that commonly measure difficulties in falling asleep or maintaining sleep to quantify the presence of insomnia. The higher the AIS score, the lower the sleep quality and mental status. The AIS identifies three types of sleep disorders: no insomnia (score below 4), suspicious (4-6), and insomnia (score between 7-24).

    6. the Athens Insomnia Scale-8 (AIS-8) [one month from baseline]

      The AIS comprises eight items that commonly measure difficulties in falling asleep or maintaining sleep to quantify the presence of insomnia. The higher the AIS score, the lower the sleep quality and mental status. The AIS identifies three types of sleep disorders: no insomnia (score below 4), suspicious (4-6), and insomnia (score between 7-24).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. 18-60 years old;

    2. primary complaint of subjective tinnitus ≤ 1 months of duration;

    3. a decline in auditory function by audiological assessments on the day of the test, of which the outcome must either satisfy one of the following conditions:

    4. a reduced distortion product otoacoustic emissions (DPOAE) amplitude in individuals with normal Pure tone audiometry (PTA) results;

    5. more than a PTA threshold > 20 dB with frequencies between 125 and 8000 Hz, but not exhibited idiopathic sudden sensorineural hearing loss;

    6. a state of good general condition;

    7. with good adherence to participation and signed informed consent.

    Exclusion Criteria:
    1. active middle ear pathology;

    2. patients who had received treatment for their current condition prior to the study;

    3. both the PTA and DPOAE with normal outcomes;

    4. hearing implants;

    5. history of known corticosteroids contraindications (including osteoporosis, peptic ulcers, poorly controlled hypertension, diabetes, chronic liver or renal insufficiency, tumorous condition, alcohol abuse, pregnant patients, and women on estrogen-containing oral contraceptive steroids).

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Eye & ENT Hospital of Fudan University

    Investigators

    • Principal Investigator: Shan Sun, Eye and ENT Hospital of Fudan University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Eye & ENT Hospital of Fudan University
    ClinicalTrials.gov Identifier:
    NCT06124703
    Other Study ID Numbers:
    • different STOP-AST regimens
    First Posted:
    Nov 9, 2023
    Last Update Posted:
    Nov 13, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 13, 2023